证券之星消息，截至2025年10月14日收盘，稳健医疗(300888)报收于38.73元，上涨0.52%，换手率 0.82%，成交量4.74万手，成交额1.84亿元。 10月14日的资金流向数据方面，主力资金净流入1446.65万元，占总成交额7.86%，游资资金净流入 153.87万元，占总成交额0.84%，散户资金净流出1600.52万元，占总成交额8.69%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-14 | 38.73 | 0.52% | 1446.65万 | 7.86% | 153.87万 | 0.84% | -1600.52万 | -8.69% | | 2025-10-13 | 38.53 | -2.31% | -766.54万 | -3.76% | -298.87万 | -1.46% | 1065.42万 | 5.22% | | 2025-10-10 | 3 ...

Company Overview - Steady Medical Products Co., Ltd. is located in Longhua District, Shenzhen, Guangdong Province, and was established on August 24, 2000. The company went public on September 17, 2020. Its main business involves the research, production, and sales of cotton products [1]. Financial Performance - As of September 3, Steady Medical's stock price fell by 4.23% to 39.60 CNY per share, with a trading volume of 397 million CNY and a turnover rate of 5.57%. The total market capitalization is 23.06 billion CNY. The stock has experienced a cumulative decline of 5.51% over the past three days [1]. Revenue Composition - The revenue composition of Steady Medical is as follows: consumer products account for 51.84%, medical consumables for 47.49%, and other (supplementary) products for 0.67% [1]. Fund Holdings - Minsheng Jianyin Fund has a significant holding in Steady Medical, with one of its funds, Minsheng Jianyin Value Discovery One-Year Holding Period Mixed A (010795), reducing its stake by 26,200 shares in the second quarter, now holding 416,500 shares, which represents 4.12% of the fund's net value, ranking as the seventh largest holding [2]. Fund Performance - The Minsheng Jianyin Value Discovery fund has a current size of 390 million CNY and has achieved a return of 23.22% year-to-date, ranking 3,233 out of 8,180 in its category. Over the past year, it has returned 35.22%, ranking 4,063 out of 7,967. Since inception, the fund has incurred a loss of 15.08% [2]. Fund Manager Information - The fund manager of Minsheng Jianyin Value Discovery is Deng Kaicheng, who has been in the position for 2 years and 239 days. The total asset size under his management is 485 million CNY, with the best fund return during his tenure being 36.05% and the worst being -4.47% [2].

Core Viewpoint - The stock of Steady Medical (300888) has shown a positive performance with a closing price of 41.87 yuan, reflecting a 2.25% increase on August 28, 2025, amidst varying capital flows from different investor groups [1][2]. Financial Performance - For the first half of 2025, Steady Medical reported a main revenue of 5.296 billion yuan, representing a year-on-year increase of 31.31% - The net profit attributable to shareholders was 492 million yuan, up 28.07% year-on-year - The net profit after deducting non-recurring gains and losses was 461 million yuan, marking a 40.9% increase year-on-year - In Q2 2025, the company achieved a single-quarter main revenue of 2.691 billion yuan, a 26.66% increase year-on-year, and a net profit of 243 million yuan, up 20.68% year-on-year [3]. Market Position - Steady Medical's total market capitalization stands at 24.382 billion yuan, significantly higher than the industry average of 11.443 billion yuan, ranking 4th in the industry - The company has a net asset value of 12.276 billion yuan, leading the industry with a ranking of 1st - The company's net profit of 492 million yuan ranks 3rd in the industry, while its price-to-earnings ratio (24.78) and price-to-book ratio (2.12) rank 4th and 5th respectively [3]. Investor Sentiment - Over the past 90 days, 19 institutions have rated the stock, with 16 buy ratings and 3 hold ratings - The average target price set by institutions for the stock is 55.82 yuan [4].

Core Viewpoint - The company,稳健医疗, is experiencing a decline in stock price and has a PE ratio lower than the industry average, indicating potential investment concerns despite strong revenue growth and market presence [1][2]. Company Overview - The company specializes in the research, production, and sales of cotton-based products across various sectors, including medical, personal care, and home care [1]. - Key products include advanced wound dressings, traditional wound care products, infection control products, and a range of personal hygiene items [1]. - The company has consistently ranked among the top three exporters of medical dressings in China and has established a strong brand presence in hospitals and pharmacies [1]. Financial Performance - For Q1 2025, the company reported a revenue of 2.605 billion yuan, representing a year-on-year increase of 36.47% [2]. - The net profit for the same period was 249 million yuan, also reflecting a year-on-year growth of 36.26% [2]. - The sales gross margin stood at 48.46%, indicating a healthy profitability level [2]. Market Position - The company's current PE ratio is 38.95, which is below the industry average of 41.61 and the median of 44.57, placing it 14th in the beauty and personal care sector [2]. - The total market capitalization of the company is approximately 29.658 billion yuan [1][2]. - Recent capital flow indicates a net inflow of 12.52 million yuan on May 12, but a total outflow of 4.9493 million yuan over the past five days [1].

Group 1 - The core viewpoint of the news highlights the performance and market position of the company, Steady Medical, in the healthcare industry, particularly in the medical dressing sector [1][2]. - As of May 9, the company's stock closed at 51.45 yuan, reflecting a 3.31% increase, with a rolling price-to-earnings (PE) ratio of 39.34 times and a total market capitalization of 29.961 billion yuan [1]. - The average PE ratio for the beauty and healthcare industry is 41.70 times, with a median of 45.39 times, placing Steady Medical at the 14th position within the industry [1][3]. Group 2 - Steady Medical specializes in the research, production, and sales of cotton-based products across various sectors, including medical, personal care, and home care [2]. - The company's main products include high-end wound dressings, traditional wound care products, infection control products, and various cotton-based personal care items [2]. - According to recent performance data, for the first quarter of 2025, the company reported revenue of 2.605 billion yuan, a year-on-year increase of 36.47%, and a net profit of 249 million yuan, also up by 36.26%, with a gross profit margin of 48.46% [2].